Arcadia Biosciences, Inc.
RKDA
$1.96
-$0.035-1.76%
| Weiss Ratings | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.31 | |||
| Price History | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.96% | |||
| 30-Day Total Return | -16.90% | |||
| 60-Day Total Return | -12.55% | |||
| 90-Day Total Return | -28.43% | |||
| Year to Date Total Return | -28.18% | |||
| 1-Year Total Return | -64.15% | |||
| 2-Year Total Return | -94.54% | |||
| 3-Year Total Return | -98.13% | |||
| 5-Year Total Return | -99.17% | |||
| 52-Week High % Change | -73.97% | |||
| 52-Week Low % Change | 2.64% | |||
| Price | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.30 | |||
| 52-Week Low Price | $1.85 | |||
| 52-Week Low Price (Date) | Apr 15, 2024 | |||
| 52-Week High Price (Date) | May 08, 2023 | |||
| Valuation | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.81M | |||
| Enterprise Value | -7.97M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -14.24 | |||
| Earnings Per Share Growth | -44.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.50 | |||
| Price/Book (Q) | 0.21 | |||
| Enterprise Value/Revenue (TTM) | -1.44 | |||
| Price | $2.09 | |||
| Enterprise Value/EBITDA (TTM) | 0.60 | |||
| Enterprise Value/EBIT | 0.59 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.36M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 214 974 8921 | |||
| Address | 5950 Sherry Lane Dallas, TX 75225 | |||
| Website | www.arcadiabio.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -245.87% | |||
| Profit Margin | -246.79% | |||
| Management Effectiveness | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -35.81% | |||
| Return on Equity | -- | |||
| Income Statement | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.67M | |||
| Total Revenue (TTM) | 5.67M | |||
| Revenue Per Share | $4.16 | |||
| Gross Profit (TTM) | 1.14M | |||
| EBITDA (TTM) | -13.64M | |||
| EBIT (TTM) | -13.93M | |||
| Net Income (TTM) | -13.98M | |||
| Net Income Avl. to Common (TTM) | -13.98M | |||
| Total Revenue Growth (Q YOY) | 57.26% | |||
| Earnings Growth (Q YOY) | 17.52% | |||
| EPS Diluted (TTM) | -14.24 | |||
| EPS Diluted Growth (Q YOY) | 66.67% | |||
| Balance Sheet | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 11.64M | |||
| Cash Per Share (Q) | $8.55 | |||
| Total Current Assets (Q) | 14.97M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 12.70M | |||
| Current Ratio (Q) | 4.170 | |||
| Book Value Per Share (Q) | $9.99 | |||
| Total Assets (Q) | 19.71M | |||
| Total Current Liabilities (Q) | 3.59M | |||
| Total Debt (Q) | 1.01M | |||
| Total Liabilities (Q) | 7.00M | |||
| Total Common Equity (Q) | 12.84M | |||
| Cash Flow | RKDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.34M | |||
| Cash from Financing (TTM) | 5.51M | |||
| Net Change in Cash (TTM) | -14.13M | |||
| Levered Free Cash Flow (TTM) | -6.05M | |||
| Cash from Operations (TTM) | -15.29M | |||
